A large investigation reported that more than half of patients receiving cellular therapies develop orthostatic hypotension within their first month, flagging a common but previously under-characterized complication for CAR-T and related platforms. The study reinforces the need for routine blood pressure monitoring during early post-infusion follow-up. Separately, an EClinicalMedicine dose-expansion cohort in advanced endometrial cancer found that an oral Wnt-blocking agent combined with lenvatinib produced durable tumor shrinkage in women whose disease progressed after chemotherapy and immunotherapy. The findings add to the evidence for pathway-targeted combinations after treatment failure. In parallel, researchers reported a first-ever electrochemotherapy case in a child with high-risk neuroblastoma, aiming to reposition the approach as a feasible option in pediatric settings. Collectively, the updates point to expanding safety surveillance and continued experimentation with combination mechanisms in late-line solid tumors and pediatric oncology.